Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του galinos.gr από το 2011 μέχρι σήμερα
 

SPC, UK: MILK OF MAGNESIA Oral Suspension (2013)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Phillips' Milk of Magnesia.

Qualitative and quantitative composition

Magnesium Hydroxide BP 415 mg per 5 ml suspension.

Pharmaceutical form

Oral Suspension.

Therapeutic indications

Milk of Magnesia is indicated as an antacid for the symptomatic relief of stomach discomfort, indigestion, hyperacidity, heartburn and flatulence; and as a laxative for constipation.

Posology and method of administration

Use a 5 ml spoon or the dosing cup provided. Doses may be taken with milk or water if desired. Do not exceed the stated dose. As an antacid Adults: 5-10 ml (one or two 5 ml spoonfuls or fill the dosing ...

Contraindications

Hypersensitivity to any of the ingredients.

Special warnings and precautions for use

Adequate fluid intake should be maintained during use. If diarrhoea occurs especially in children or the elderly, discontinue use immediately. In case of renal impairment a doctor should be consulted as ...

Interaction with other medicinal products and other forms of interaction

Magnesium hydroxide may interfere locally with the absorption of other drugs taken orally by increasing gastric pH. This can be avoided by giving other drugs 2-3 hours before the administration of magnesium ...

Pregnancy and lactation

For Magnesium hydroxide no clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, ...

Effects on ability to drive and use machines

Magnesium hydroxide is unlikely to cause any effects on the ability to drive and use machines.

Undesirable effects

Diarrhoea may occur which is dose related. In patients with impaired renal function there may be sufficient accumulation of magnesium to produce toxic effects (see section 4.9).

Overdose

Symptoms of overdose include gastrointestinal irritation and watery diarrhoea. Magnesium poisoning may produce hypermagnesaemia, symptoms of which include nausea, vomiting, flushing, thirst, hypotension, ...

Pharmacodynamic properties

Magnesium hydroxide is practically insoluble in water and solution is not effected until the hydroxide reacts with hydrochloric acid in the stomach to form magnesium chloride. Its neutralising action is ...

Pharmacokinetic properties

Magnesium hydroxide exerts its antacid therapeutic effect rapidly within the gastro-intestinal tract following oral administration and this action is therefore independent of pharmacokinetic properties. ...

Preclinical safety data

Magnesium hydroxide has been used for many years and no further data are presented in this section.

List of excipients

Sodium Hydrogen Carbonate EP Oil of Peppermint EP Glycerol EP Sodium Saccharin EP Purified Water EP

Incompatibilities

None.

Shelf life

Shelf life: 36 months; after opening, 6 months.

Special precautions for storage

Store below 25°C. Do not freeze.

Nature and contents of container

Blue HDPE bottles with white HDPE screw turn tamper evident inner cap and external click on dosing cap. Pack size 100ml and 200ml.

Special precautions for disposal and other handling

Shake bottle well before use. Use within 6 months of opening.

Marketing authorization holder

Omega Pharma Ltd., 1<sup>st</sup> Floor, 32 Vauxhall Bridge Road, LONDON, SW1V 2SA, United Kingdom

Marketing authorization number(s)

PL 02855/0072

Date of first authorization / renewal of the authorization

22<sup>nd</sup> March 1999

Date of revision of the text

9<sup>th</sup> July 2013

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

File
application/pdf - 66,1 KB